Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EPS (Weighted Average and Diluted) (2017 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed EPS (Weighted Average and Diluted) for 12 consecutive years, with $0.22 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 115.83% year-over-year to $0.22, compared with a TTM value of $1.6 through Dec 2025, up 131.01%, and an annual FY2025 reading of -$0.01, up 99.8% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.22 for Q4 2025 at Arrowhead Pharmaceuticals, up from -$0.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.91 in Q1 2025 and bottomed at -$1.39 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.48, with a median of -$0.64 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 326.67% in 2024, then soared 385.29% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.6 in 2021, then soared by 35.0% to -$0.39 in 2022, then tumbled by 217.95% to -$1.24 in 2023, then decreased by 12.1% to -$1.39 in 2024, then surged by 115.83% to $0.22 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ARWR at $0.22 in Q4 2025, -$0.27 in Q3 2025, and -$1.26 in Q2 2025.